13F Pro quality score
Rank #2,664 of 2,925
Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.
Reported revenue, net income and operating margin by fiscal year, from Marker Therapeutics, Inc.'s annual filings on SEC EDGAR.
| Period | Form | Revenue | Net income | Op. marginOperating margin |
|---|---|---|---|---|
| FY 2025 | 10-K | $3.5M | $-12.2M | — |
| FY 2024 | 10-K | $6.6M | $-10.7M | -168.7% |
| FY 2023 | 10-K | $3.3M | $-8.2M | — |
| FY 2022 | 10-K | $3.5M | $-29.9M | — |
| FY 2020 | 10-K | $500.0K | $-28.7M | — |
| FY 2019 | 10-K | $213.2K | $-21.4M | — |
Marker Therapeutics, Inc. (MRKR) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MRKR at 24.3/100 on a composite quality score built from its SEC filings, placing it at rank #2,664 of 2,925 stocks — the bottom half of the AI-ranked universe. Top institutional holders of MRKR by reported 13-F value include NEA Management Company, Blue Owl Capital, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. MRKR trades on the Nasdaq exchange and files with the SEC under CIK 1094038. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MRKR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Marker Therapeutics, Inc. directly from SEC EDGAR.
Financials through the period ended SEC EDGAR: CIK 1094038 →